Targeting the αvβ3 integrin for small-animal PET/CT of osteolytic bone metastases

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1873-1880

  Wadas, Thaddeus J ^a   Deng, Hongju ^b   Sprague, Jennifer E ^a,b   Zheleznyak, Alexander ^a   Weilbaecher, Katherine N ^b   Anderson, Carolyn J ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Bisphosphonate; Bone; Integrin; Metastasis; PET

Indexed keywords

64CU CB TE2A C(RGDYK); ACID PHOSPHATASE; EOSIN; HEMATOXYLIN; RADIOPHARMACEUTICAL AGENT; TARTARIC ACID; TAX PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ZOLEDRONIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COPPER; DIAGNOSTIC AGENT; INTEGRIN ALPHAVBETA1; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE LESION; BONE METASTASIS; CLINICAL EVALUATION; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HINDLIMB; HISTOLOGY; INFLAMMATION; MICROENVIRONMENT; MONITORING; MOUSE; NONHUMAN; OSTEOCLAST; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIL; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR CELL; VERTEBRA; WILD TYPE; ANIMAL; BONE TUMOR; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METASTASIS; MULTIPLE MYELOMA; OSTEOLYSIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; SPINE; T CELL LEUKEMIA; TREATMENT OUTCOME;

ANIMALS; BONE NEOPLASMS; COPPER RADIOISOTOPES; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE PRODUCTS, TAX; HUMANS; LEUKEMIA, T-CELL; MICE; MULTIPLE MYELOMA; OLIGOPEPTIDES; OSTEOCLASTS; OSTEOLYSIS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, VITRONECTIN; SPINE; TAIL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70350702817     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.067140     Document Type: Article

References (32)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
2. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953. (Pubitemid 41079914)
3. 18F-fluoride PET/CT. J Nucl Med. 2008;49:414-421.
4. Bombardieri E, Crippa F. PET imaging in breast cancer. Q J Nucl Med. 2001;45:245-256.
5. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000;88:2927-2933. (Pubitemid 30413175)
6. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431-435. (Pubitemid 28136839)
7. Liu W, Hajibeigi A, Lin M, et al. An osteoclast-targeting agent for imaging and therapy of bone metastasis. Bioorg Med Chem Lett. 2008;18:4789-4793.
8. Bhushan KR, Tanaka E, Frangioni JV. Synthesis of conjugatable bisphosphonates for molecular imaging of large animals. Angew Chem Int Ed Eng. 2007;46:7969-7971. (Pubitemid 350033468)
9. Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007; 40:122-131. (Pubitemid 44839339)
10. Kim MK, Kim HD, Park JH, et al. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-f1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3- oxopiperidin- 4-ylcarbamoylg-cyclohexyl-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J Pharmacol Exp Ther. 2006;318:555-562.
11. Tanaka S, Nakamura K, Oda H. The osteoclast: a potential therapeutic target of bone and joint destruction in rheumatoid arthritis. Mod Rheumatol. 2001; 11:177-183. (Pubitemid 33040865)
12. Nicholson GC, Malakellis M, Collier FM, et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor κB ligand (RANKL). Clin Sci. 2000;99:133-140. (Pubitemid 30614381)
13. 3 integrin after murine hindlimb ischemia. Circulation. 2005;111:3255-3260.
14. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561-565. (Pubitemid 38297190)
15. 3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA. 2003;100:14205-14210.
16. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci. 1998;54:541-548. (Pubitemid 28325627)
17. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
18. Chen X, Park R, Shahinian Anthony H, et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189. (Pubitemid 38315112)
19. 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
20. 64Cu-labeled RGD peptide. J Nucl Med. 2007;48:311-318.
21. Qaim SM, Bisinger T, Hilgers K, Nayak D, Coenen HH. Positron emission intensities in the decay of copper-64, bromine-76 and iodine-124. Radiochim Acta. 2007;95(2):67-73.
22. McCarthy DW, Shefer RE, Klinkowstein RE, et al. The efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
23. + complexation in a diamond-lattice cleft. J Am Chem Soc. 1990;112:8604-8605.
24. Grossman WJ, Kimata JT, Wong F-H, Zutter M, Ley T, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92:1057-1061.
25. Wadas TJ, Anderson CJ. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc. 2007;1:3062-3068.
26. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474. (Pubitemid 38327472)
27. Sun X, Wuest M, Weisman Gary R, et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem. 2002;45:469-477. (Pubitemid 34073464)
28. Hendey B, Lawson M, Marcantonio EE, Maxfield FR. Intracellular calcium and calcineurin regulate neutrophil motility on vitronectin through a receptor identified by antibodies to integrins αv and β3. Blood. 1996;87:2038-2048. (Pubitemid 26068920)
29. Gao L, Deng H, Zhao H, et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood. 2005;106: 4294-4302. (Pubitemid 41775939)
30. 3 integrin "vitronectin receptor." Int J Biochem Cell Biol. 1997;29:721-725.
31. Padalecki SS, Guise TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res. 2002;4:35-41. (Pubitemid 34097555)
32. Russell RGG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-257. (Pubitemid 350191297)